Q1 2026 EPS Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Lowered by Analyst

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Investment analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued to clients and investors on Tuesday, April 23rd. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $2.01 for the quarter, down from their prior estimate of $2.09. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.13 per share.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The firm had revenue of $396.80 million for the quarter, compared to analysts’ expectations of $387.18 million. During the same quarter last year, the firm earned ($1.24) earnings per share. The firm’s revenue for the quarter was up 53.6% compared to the same quarter last year.

A number of other research analysts have also recently weighed in on the company. Mizuho lifted their target price on Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. UBS Group boosted their price objective on Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Wedbush restated an “outperform” rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. TheStreet upgraded Sarepta Therapeutics from a “d” rating to a “c-” rating in a research note on Monday, March 4th. Finally, Royal Bank of Canada boosted their price objective on Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $158.38.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock opened at $124.25 on Wednesday. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $159.89. The stock has a market capitalization of $11.67 billion, a P/E ratio of -20.30 and a beta of 0.94. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32. The business’s fifty day moving average price is $126.18 and its 200 day moving average price is $110.31.

Insider Activity at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 761 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the sale, the director now directly owns 7,516 shares of the company’s stock, valued at $923,941.88. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the transaction, the director now directly owns 7,516 shares of the company’s stock, valued at $923,941.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.30, for a total value of $153,960.00. Following the transaction, the chief financial officer now directly owns 39,114 shares of the company’s stock, valued at $5,018,326.20. The disclosure for this sale can be found here. Insiders sold a total of 22,096 shares of company stock valued at $2,739,419 over the last three months. 7.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors have recently made changes to their positions in SRPT. Capital International Investors grew its holdings in shares of Sarepta Therapeutics by 160.0% during the fourth quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock valued at $457,221,000 after purchasing an additional 2,917,797 shares during the last quarter. Norges Bank acquired a new position in shares of Sarepta Therapeutics during the fourth quarter worth approximately $80,697,000. Bank of Nova Scotia acquired a new position in shares of Sarepta Therapeutics during the fourth quarter worth approximately $50,990,000. Avoro Capital Advisors LLC boosted its position in shares of Sarepta Therapeutics by 7.9% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after buying an additional 319,444 shares during the period. Finally, Mizuho Markets Americas LLC acquired a new position in shares of Sarepta Therapeutics during the third quarter worth approximately $29,813,000. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.